IV Racemic Ketamine vs Esketamine (Spravato): A Clinical Comparison

Overview

The treatment of treatment-resistant depression now involves two distinct ketamine-based options. IV racemic ketamine delivers both S(+)-ketamine (esketamine) and R(-)-ketamine (arketamine) in equal proportions via intravenous infusion. Esketamine (Spravato), the purified S-enantiomer delivered intranasally, received FDA approval in March 2019 for TRD and later for MDD with acute suicidal ideation. This comparison examines the clinical evidence, practical considerations, and economic factors distinguishing these approaches.

Mechanism of Action

Both IV racemic ketamine and esketamine exert their primary antidepressant effects through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, triggering a cascade of downstream effects including enhanced alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor signaling, increased brain-derived neurotrophic factor (BDNF) release, and activation of the mechanistic target of rapamycin (mTOR) pathway, which collectively promote rapid synaptic plasticity and neurogenesis (Abdallah et al., 2015).

However, the racemic mixture contains arketamine in addition to esketamine. Preclinical research suggests that arketamine may contribute unique antidepressant properties through sigma-1 receptor modulation, enhanced AMPA-to-NMDA signaling ratios, and potentially more sustained BDNF-TrkB pathway engagement (Yang et al., 2015). Whether these preclinical differences translate into meaningful clinical advantages for racemic ketamine over the purified S-enantiomer remains an active area of investigation.

Esketamine has approximately 3-4 times greater affinity for the NMDA receptor than arketamine, making it the more potent NMDA antagonist. This higher potency partly explains the rationale for developing it as a standalone pharmaceutical product. However, potency at a single receptor does not necessarily predict superior overall antidepressant efficacy, particularly given the multi-target nature of ketamine's mechanism.

Efficacy Comparison

The evidence base for IV racemic ketamine in depression is extensive, with over 40 randomized controlled trials and multiple meta-analyses demonstrating robust antidepressant effects. A landmark meta-analysis by Kishimoto et al. (2016), published in Psychological Medicine, analyzed 14 RCTs and found that IV ketamine at 0.5 mg/kg produced significantly greater antidepressant responses than placebo at 24 hours (OR = 9.87, 95% CI 4.37-22.29).

Esketamine's evidence base is anchored by five pivotal phase III trials (TRANSFORM-1, TRANSFORM-2, TRANSFORM-3, SUSTAIN-1, and SUSTAIN-2). TRANSFORM-2 (Popova et al., 2019) demonstrated that esketamine nasal spray plus an oral antidepressant produced statistically significant improvement in MADRS scores compared with placebo nasal spray plus oral antidepressant at day 28 (least-squares mean difference of -4.0 points, p=0.020).

Clinical: Direct head-to-head comparisons between IV racemic ketamine and intranasal esketamine remain limited. The few available studies, including Correia-Melo et al. (2020) in the British Journal of Psychiatry, suggest comparable acute antidepressant efficacy when routes are matched (both IV). Clinicians should note that most comparative inferences are drawn across trials with different designs, populations, and outcome measures.

FDA Status and Regulatory Framework

IV racemic ketamine is FDA-approved only as an anesthetic agent. Its use for depression is entirely off-label, meaning there is no FDA-mandated dosing protocol, monitoring requirement, or Risk Evaluation and Mitigation Strategy (REMS). While this provides clinical flexibility, it also means that insurance coverage is inconsistent and standardization of care varies widely across providers.

Esketamine's FDA approval established a specific REMS program requiring administration in certified healthcare settings, with patients monitored for at least two hours post-dose. The REMS was designed to address safety concerns including sedation, dissociation, and potential misuse. While the REMS framework standardizes care, it also limits treatment to certified facilities and restricts at-home administration.

Cost and Insurance Coverage

The cost differential between generic IV racemic ketamine and branded esketamine is substantial. Generic ketamine solution costs approximately $5-15 per treatment dose, while the Spravato device carries a wholesale acquisition cost of $590 (56 mg) to $885 (84 mg) per session. When facility, monitoring, and staffing costs are included, total per-session costs differ by roughly 2-3 fold.

However, insurance coverage significantly modifies the patient's out-of-pocket experience. Because esketamine has FDA approval, commercial insurers and Medicare are more likely to cover it (typically with prior authorization documenting treatment resistance). Janssen's copay assistance program can reduce out-of-pocket costs to $10 per session for eligible commercially insured patients. IV ketamine, being off-label, is rarely covered by insurance, meaning patients typically pay the full per-session fee.

Clinical: When counseling patients on cost, consider the total economic picture: a patient with commercial insurance and copay assistance may pay substantially less out-of-pocket for esketamine than for self-pay IV ketamine, despite esketamine's higher list price. Conversely, uninsured or underinsured patients will almost always find IV ketamine more affordable.

Side Effect Profiles

Both treatments share a similar acute side effect profile dominated by dissociative symptoms, transient blood pressure elevation, and sedation. These effects are generally self-limiting, resolving within 1-2 hours of treatment. Cardiovascular monitoring is recommended for both, with blood pressure measurement before and during treatment.

IV racemic ketamine may produce more pronounced hemodynamic effects due to higher peak plasma concentrations. Intranasal esketamine produces a lower, more gradual peak, which may contribute to a somewhat more tolerable hemodynamic profile. However, esketamine-specific nasal side effects (dysgeusia, nasal discomfort, rhinorrhea) represent an additional burden not present with IV administration. Long-term safety concerns including cognitive effects and abuse potential apply to both treatments and remain under active surveillance.

Practical Considerations for Treatment Selection

Several clinical factors may guide the choice between IV racemic ketamine and esketamine:

• Insurance status: Patients with commercial insurance may benefit from esketamine's coverage pathway and copay assistance
• Prior treatment history: Patients who have failed esketamine may be candidates for IV racemic ketamine (and vice versa), given the potentially distinct pharmacological contributions of arketamine
• Provider availability: Not all regions have both REMS-certified esketamine providers and IV ketamine clinics
• Dosing flexibility: IV racemic ketamine allows individualized dose titration (typically 0.5 mg/kg but adjustable), while esketamine has fixed doses (56 mg or 84 mg)
• Patient preference: Some patients prefer IV administration for its precision; others prefer the non-invasive nasal spray

References

• Abdallah CG, Adams TG, Kelmendi B, et al. (2016). Ketamine's Mechanism of Action: A Path to Rapid-Acting Antidepressants. Depression and Anxiety, 33(8), 689-697. PubMed
• Correia-Melo FS, Leal GC, Vieira F, et al. (2020). Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of Affective Disorders, 264, 527-534. PubMed
• Kishimoto T, Chawla JM, Hagi K, et al. (2016). Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 46(7), 1459-1472. PubMed
• Popova V, Daly EJ, Trivedi M, et al. (2019). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. American Journal of Psychiatry, 176(6), 428-438. PubMed
• Yang C, Shirayama Y, Zhang JC, et al. (2015). R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Translational Psychiatry, 5(9), e632. PubMed
• National Institute of Mental Health (NIMH). Treatment-Resistant Depression. NIMH